Siemens Healthineers ( (SEMHF) ) has released its Q3 earnings. Here is a breakdown of the information Siemens Healthineers presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Siemens Healthineers is a leading global medical technology company specializing in imaging, diagnostics, and advanced therapies, with a focus on healthcare innovations that improve patient outcomes worldwide.
In its third quarter of fiscal year 2025, Siemens Healthineers reported significant revenue growth and increased profitability, driven by strong performances in its Imaging and Varian segments, despite challenges in the Diagnostics segment.
The company achieved a 7.6% increase in comparable revenue, reaching nearly €5.7 billion, with notable contributions from the Imaging segment, which saw an 11.7% growth, and the Varian segment, which grew by 8.7%. The adjusted EBIT margin improved to 16.8%, and free cash flow surged by over 50% to €844 million. Adjusted basic earnings per share rose to €0.64, reflecting a 23% increase from the previous year.
Despite a slight decline in the Diagnostics segment revenue, the company benefited from cost reductions and a favorable business mix. The Advanced Therapies segment also saw a modest revenue increase of 4.5%. Geographically, the Americas and Asia Pacific Japan regions experienced strong revenue growth, while the EMEA region posted a slight increase.
Looking ahead, Siemens Healthineers has updated its fiscal year 2025 outlook, anticipating a comparable revenue growth of 5.5% to 6% and adjusted basic earnings per share between €2.30 and €2.45, reflecting confidence in its continued performance amidst geopolitical uncertainties.